Shingles Vaccine Linked to 20% Lower Dementia Risk in a Natural Experiment

CATEGORY: DISEASE PREVENTION

Older adults in Wales who received the shingles vaccine were about 20% less likely to be newly diagnosed with dementia over the following seven years than otherwise similar adults who were not eligible for the shot.¹ Shingles is a painful, blistering rash caused when the chickenpox virus, dormant in your nerves for decades, reactivates later in life. Dementia is the gradual loss of memory and thinking that eventually interferes with daily living. The link between the two is surprising, and what makes this finding stand out is not just the size of the effect but the unusually clean way the researchers were able to measure it.

How the Study Worked

Most vaccine research struggles with a stubborn problem: people who choose to get vaccinated often differ from those who do not, in health, habits, and access to care. This study sidestepped that using what scientists call a natural experiment. When Wales launched its shingles vaccination program in 2013, eligibility was set by exact date of birth. People born on or after 2 September 1933 were offered the vaccine, while those born just before that date were shut out for life.¹ Someone born a single week on either side of the cutoff is essentially identical in age and background, yet one group had access to the shot and the other did not, much like the coin flip of a randomized trial. The researchers then tracked new dementia diagnoses over seven years using electronic health records from primary and secondary care, plus death certificates that listed dementia as a cause.

What the Numbers Mean

Being eligible for and receiving the vaccine was associated with a 3.5 percentage point drop in the chance of a new dementia diagnosis over those seven years, which works out to a 20% relative reduction.¹ In plain terms, for every 100 comparable older adults, roughly three to four fewer developed dementia in the vaccinated group. The protective association was noticeably stronger in women than in men, though the study could not fully explain why. It is worth noting this involved the older, live-attenuated version of the shingles vaccine known as Zostavax, not the newer formulation now used in many countries.

Why a Vaccine Might Touch the Brain

Researchers have several working ideas, none yet proven. The chickenpox virus, called varicella-zoster, never fully leaves your body; it hides in nerve cells and can flare up as shingles when your immune defenses weaken with age. Some scientists suspect that repeated viral reactivation, and the inflammation it triggers in and around the brain, may contribute to the damage seen in dementia. By keeping the virus in check, the vaccine might reduce that low-grade inflammatory wear and tear. It is also possible the vaccine gives the aging immune system a broader tune-up. These are hypotheses the study was not designed to confirm.

Reasons for Caution

Because eligibility hinged on a birthday rather than personal choice, this design comes closer to showing cause and effect than a typical observational study, where researchers simply watch who happens to get vaccinated. Even so, this is one study in one population, and a single finding is a starting point, not a settled conclusion. Dementia has many contributors, including genetics, blood pressure, hearing loss, and other factors, so no single shot is a shield against it. A vaccine decision is a personal medical choice that depends on your age, health, and which formulation is available where you live, and the shingles vaccine’s primary, well-established benefit remains preventing shingles itself and its complications.

Key Takeaways

• In a rigorous natural experiment, eligibility for the shingles vaccine was linked to a 20% lower chance of a new dementia diagnosis over seven years, with a stronger association in women.
• The clever birthdate-based design makes this stronger evidence than a typical observational study, but it is still a single finding and not proof that the vaccine prevents dementia for everyone.
• If you are weighing the shingles vaccine, its confirmed benefit is preventing shingles; any effect on dementia risk is a promising but unconfirmed bonus worth discussing with your doctor.
• Talk to your healthcare provider before making decisions about vaccination, especially if you have a weakened immune system or other health conditions.

References

1. Eyting M, Xie M, Michalik F, et al. A natural experiment on the effect of herpes zoster vaccination on dementia. Nature. 2025;641(8062):438–446. link